Cytokinetics (CYTK) EBIAT (2016 - 2025)
Historic EBIAT for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to -$150.0 million.
- Cytokinetics' EBIAT fell 958.68% to -$150.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$589.5 million, marking a year-over-year decrease of 1202.52%. This contributed to the annual value of -$589.5 million for FY2024, which is 1202.52% down from last year.
- Per Cytokinetics' latest filing, its EBIAT stood at -$150.0 million for Q4 2024, which was down 958.68% from -$160.5 million recorded in Q3 2024.
- In the past 5 years, Cytokinetics' EBIAT registered a high of -$3.2 million during Q3 2020, and its lowest value of -$160.5 million during Q3 2024.
- For the 5-year period, Cytokinetics' EBIAT averaged around -$92.4 million, with its median value being -$109.0 million (2022).
- Its EBIAT has fluctuated over the past 5 years, first surged by 8926.39% in 2020, then plummeted by 229640.94% in 2021.
- Over the past 5 years, Cytokinetics' EBIAT (Quarter) stood at -$43.9 million in 2020, then skyrocketed by 30.41% to -$30.6 million in 2021, then crashed by 349.39% to -$137.4 million in 2022, then increased by 0.35% to -$136.9 million in 2023, then fell by 9.59% to -$150.0 million in 2024.
- Its last three reported values are -$150.0 million in Q4 2024, -$160.5 million for Q3 2024, and -$143.3 million during Q2 2024.